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Abstract
Background Currently, people live longer but often with
poor quality of life. The decrease in healthy life-years is
partly attributable to the institution of polypharmacy to
treat various comorbidities.
Objectives The objectives of the study were to deter-
mine the prevalence and nature of drug-related problems
(DRPs) in polypharmacy elderly patients residing in
nursing homes and to test the acceptability of a pharma-
cist’s intervention.
Methods An exposure cohort was constituted in three
Portuguese nursing homes, where all polypharmacy (five or
more medicines) elderly patients (C65 years of age) were
analysed and then a random stratified sample was extracted
to be subject to an intervention. Clinical and therapeutic
data were collected and analysed for DRPs and classified
according to the II Granada Consensus, by a pharmacist-led
team. The intervention was the formulation of a pharma-
cist’s recommendations to prescribers addressing clinically
relevant DRPs, along with suggestions for therapy changes.
Results The initial sample included 126 elderly patients
taking 1332 medicines, where 2109 DRPs were identified.
The exposure cohort included 63 patients, with comparable
baseline data (p[ 0.005). Manifest DRPs occurred in
31.7 % of the intervention group (mainly quantitative
ineffectiveness–DRP 4), whereas potential DRPs were
identified in 100 % of patients (mainly non-quantitative
unsafe–DRP 5). Amongst the DRPs identified, 584
(56.7 %) were reported to prescribers (all types of DRPs)
and 113 (11 %) to nurses (only non-quantitative ineffec-
tiveness–DRP 3). A total of 539 pharmacist recommenda-
tions were presented to physicians, corresponding to 62
letters sent by mail, each including an average of 8.7 rec-
ommendations to solve DRPs present in intervention group
(IG) patients. There was a high non-response rate (n = 34
letters; 54.8 %; containing 367 pharmacist recommenda-
tions; 68.1 %) and amongst recommendations receiving
feedback, only 8.7 % of pharmacist recommendations
made were accepted (n = 15). Positive responses were
significantly associated with a lower number of recom-
mendations made, whereas a higher number of recom-
mendations increased the odds of no response (p\ 0.001).
Conclusion A pharmacist-led medication review proved
useful in identifying DRPs in elderly polypharmacy nurs-
ing home residents. Stronger bonds must be developed
between healthcare professionals to increase patient safety
in the vulnerable institutionalised elderly population.
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Key Points
The Granada Classification for drug-related
problems proved useful in guiding a pharmacist-led
medication review in elderly patients.
Nearly three manifest drug-related problems were
detected in polypharmacy elderly patients, which
could have been prevented.
Collaboration between pharmacists, nurses and
doctors can improve the rational use of medicines.
Effective communication with physicians may be
fostered by reducing the number of pharmacist
recommendations.
1 Introduction
For the past decades, people have been living longer.
Portugal is currently one of Europe’s leading countries in
terms of life expectancy with an age index registered in
2014 of 138.6 % [1]. This demographic change is
attributable to various factors, where health technology
plays an important role. Medicines are undoubtedly an
effective tool to promote better health, provided they are
rationally used. The current challenge for healthcare pro-
fessionals has shifted from increasing people’s life to
achieving a better quality of life. The fact that Portugal’s
data on healthy life-years after age 65 years do not match
the country ranking in terms of longevity is a cause of
concern. Focus has centred on the use of potentially
inappropriate medication (PIM) in elderly patients, which
is in fact a type of drug-related problem (DRP). Various
tools have been developed to identify PIM and to alert
doctors to the most appropriate treatment, with the ultimate
goal of achieving a more rational pharmacotherapy and
better patient outcomes [2–4].
Pharmacist-led medication review is an area, within
pharmaceutical care, currently attracting much attention,
which can be performed using explicit or implicit criteria.
Most of the interventions made in nursing homes use
explicit criteria. These are much simpler to use when a type
1 medication review is undertaken [5], i.e. when all
information is based exclusively on patient medical records
and no information is obtained from the patient. Literature
describing interventions in institutionalised elderly
patients, where a medication review focusses on the iden-
tification of DRP, is very scarce and the few published
studies have used different DRP classifications, making
comparisons very difficult [6]. In Portugal, only three
studies have been found evaluating DRPs in nursing
homes, two of them focussing on the detection of PIM,
either using the STOPP/START criteria [7] or Beers cri-
teria [8]. The third study focussed on the use of the med-
ication regimen complexity index, which measures the
number of medicines and dosages, but not the quality of
pharmacotherapy or its outcome [9]. Internationally, there
are various papers published using different criteria for
identifying PIM, but the Beers criteria are the most used
worldwide. The START/STOPP criteria have been gaining
prominence in Europe [10] and there are reports using the
McLeod criteria [11], Priscus list [12] and even nationally
developed classifications [13, 14]. However, few reports of
pharmacist-led medication reviews focus on the identifi-
cation of DRPs, and these have either used the Pharma-
ceutical Care Network Europe classification [15, 16] or the
DOCUMENT classification [17]. The Dader method has
been used in nursing homes [18] but, to our knowledge, no
paper has yet described the nature of DRP detected using
the Granada classification to guide pharmacist-led medi-
cation reviews [19, 20]. Therefore, this study aimed at
determining the prevalence of manifest and potential DRPs
in polypharmacy elderly patients residing in nursing homes
and to describe the nature of DRPs using the Granada
classification. Furthermore, the study aimed to test the
acceptability of a pharmacist’s intervention intending to
solve the DRPs detected.
2 Methods
2.1 Study Design
An exposure cohort was constituted in four Portuguese
nursing homes, where all polypharmacy (five or more
medicines) elderly patients (C65 years of age) were anal-
ysed and then a random stratified sample was extracted to
be subject to an intervention. These were compared with
the remaining, meeting the inclusion criteria, to assess
representativeness.
2.2 Sample of Nursing Homes
Four nursing homes were invited to participate in the study,
two located in Alentejo and another two in Lisboa and the
Vale do Tejo region. Nursing homes were chosen using
geographical convenience sampling. Data collection was
primarily ensured by two trainee pharmacists, and each of
them was responsible for two facilities. The location was
chosen according to the place where they were practicing,
as data collection was undertaken during their pre-regis-
tration training. Eligibility criteria were also defined for the
nursing homes, including completeness of fundamental
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variables (primary diagnosis and prescribed therapy) in the
medical records.
2.3 Sample of Patients
Eligible patients were polypharmacy (taking five or more
medicines at the time of study) elderly patients (C65 years
of age).
2.4 Study Period
The study started in October 2013. The interventions were
carried out during August and September 2014 and results
evaluated in October 2014.
2.5 Collected Data
All data analysed were retrieved from medical records and
included sociodemographic information and clinical and
therapeutic data (the latter checked in medication charts).
Clinical data collected included: medical diagnoses, labo-
ratory tests and measurements of clinical biomarkers, and
eventual hospitalisations.
Medicines prescribed were classified according to the
ATC (Anatomic Therapeutic Chemical) classification pro-
posed by the World Health Organization [21].
Patients’ medical conditions, negative outcomes and
medicines used were analysed using information contained
in the medical records and in medication charts.
DRPs were identified by two trainee pharmacists, who
created a database with raw data and their findings. This
database was subsequently reviewed by members of the
research team specialised in pharmaceutical care, involving
two clinical pharmacists and a physician. One of the
reviewers (clinical pharmacist) checked all records, whilst
the other two checked only records where there was
uncertainty.
DRP were searched in all patients and, when present,
classified according to the II Granada Consensus [19, 20],
which divides DRPs into three main categories: necessity,
effectiveness and safety (Fig. 1).
A negative outcome, defined as a manifest DRP, was
considered when the medical record included information
that allowed the researchers to verify that the problem had
actually occurred, such as a raise in blood pressure (in-
effectiveness) or the experience of an adverse drug
reaction (safety). The remaining DRPs were considered as
potential.
2.6 Intervention
The intervention consisted of the prioritisation of DRPs, a
report of those identified and considered clinically relevant
in the intervention group to prescribers and nurses, with the
provision of a pharmacist’s recommendation. This phar-
macist’s recommendation when headed for physicians
could include suggestions of therapy changes if appropri-
ate. Each recommendation could address one or various
DRPs, as the pharmacist’s recommendations could solve or
prevent more than one DRP at the same time. The language
used in the letters sent to physicians did not include the
mention of DRPs in an effort to make it more meaningful
to the target audience.
2.7 Outcome Measures
For all patients, the outcome measures were quantification
and qualification of identified DRPs and their classification
as potential or manifest. For the intervention group, process
measures also included the number of DRPs reported and
the number of pharmacist recommendations made to
physicians; the proportion of pharmacist recommendations
accepted was used as an outcome measure; Fig. 2 depicts
the study schema.
Safety DRP 
Drug taken presents a (potential or 
manifest) problem (DRP) 
Necessity DRP Effectiveness DRP 
Untreated 
condition 
(DRP 1) 
Unnecessary 
treatment 
(DRP 2) 
The drug is 
ineffective for 
non-quantitative 
motives (DRP 3) 
The drug is
ineffective for 
quantitative 
motives (DRP 4) 
The drug is 
unsafe for non-
quantitative 
motives (DRP 5) 
The drug is 
unsafe for 
quantitative 
motives (DRP 6) 
Fig. 1 Schematic of the II Granada Classification for drug-related problems (DRP)
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2.8 Data Analysis
Data analysis was performed using the IBM software SPSS
(IBM SPSS Statistics for Windows, IBM Corp, Armonk,
NY. Released 2012), version 21.0 and the main variables
characterised using univariate analysis (relative and abso-
lute frequencies for categorical variables and central ten-
dency and dispersion measures for continuous variables).
Patients residing in the nursing homes 
studied (n=225) 
Polypharmacy ( 5 medications) elderly (
65 years) (n=161) 
Patients’ Inclusion criteria 
Patients with complete medical records 
(n=126) 
Facilities’ Inclusion criteria 
Analysis for nature and prevalence of 
DRP and for predictors of DRP (n=126) 
Random extraction clustered by 
facility 
Comparison group (n=63)  
Used to assess representativeness of 
intervention group (table 1)
Manifest DRPs and clinically 
relevant potential DRPs prioritized 
and reported (n=697; 69.6%) 
Pharmacist analysed medication 
and detected 1002 DRPs 
Intervention group (n=63)
Pharmacists’ Recommendations to 
physicians (n=539), written in (n=62 letters) 
addressing 584 DRPs* 
Pharmacists’ recommendations to nurses 
(n=63) addressing 113 DRPs 
No feedback obtained to 34 letters (54.8%), 
addressing 367 pharmacist’s 
recommendations (68.1%) 
Response obtained to 28 letter (45.2%), 
addressing 172 pharmacist’s 
recommendations (31.9%) 
Positive response to 10 letters (35.7%; at least 
one recommendation); acceptance of 15 
pharmacist’s recommendations (8.7% from 172)
Negative response to 18 letters (64.3%); 
declining all pharmacist’s recommendations 
made (n=170) 
Fig. 2 Flow chart of study schema. DRP drug-related problems. *Note: Some pharmacist’s recommendations addressed more than one DRP
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Bivariate analysis was used to answer hypotheses previ-
ously established. Because sample distribution was not
normal (Kolmogorov–Smirnov test), mostly non-paramet-
ric tests were used and included the Chi-square test,
Spearman’s correlation coefficient and Mann–Whitney or
Kruskal–Wallis tests, according to the type of variables. A
confidence interval of 95 % was considered for all tests.
3 Results
All four facilities invited accepted to participate in the
study, totalling 225 elderly patients, of whom 161 patients
met the inclusion criteria (C65 years of age, taking five or
more medications). However, one facility, from Alentejo,
was subsequently excluded because of data incomplete-
ness, making the final group 126 polypharmacy elderly
patients from three facilities in Portugal.
3.1 Frequency and Nature of DRPs Identified (All
Patients)
The sample of 126 patients, taking a total of 1332
medicines, comprised mainly female individuals (n = 87;
69 %), with a mean age of 84.8 years [standard deviation
(SD) = 6.1], median of four registered comorbidities and
being treated with over ten medicines (median = 10;
mean = 10.6; SD = 4.2). A median of 14.5 DRPs
(SD = 8.4) were detected per patient, considering both
potential and manifest.
Patients were randomly assigned to the intervention
group using stratified sampling (n = 63), and their char-
acteristics compared with the control group (n = 63) to
assess representativeness (Table 1). Groups were shown to
be comparable at baseline.
All 1332 medicines being taken by all polypharmacy
patients (n = 126) were classified according to the ATC
classification. Figure 3 depicts the pharmacotherapeutic
classes more frequently involved in polypharmacy. The
three leading groups found accounted for 75 % of the drugs
prescribed: central nervous system (30.5 %), cardiovascu-
lar system (24.5 %) and gastrointestinal tract (19.8 %).
All patients’ demographic and medical characteristics
were explored as potential determinants for polypharmacy.
Data indicate that the number of comorbidities was mod-
erately but significantly correlated with the number of
prescribed medicines (Table 2).
All patients (n = 126) were assessed for potential or
manifest DRP where a total of 2109 DRPs were identified.
Every patient had at least one DRP. The most commonly
found DRP belonged to the safety domain (n = 922;
43.7 %), followed by necessity (n = 727; 34.5 %) and last
by effectiveness (n = 460; 21.8 %). Considering the second
level of this classification, the order found was: unsafe drug
(non-quantitative, DRP 5) (n = 741; 35.1 %), unnecessary
treatment (DRP 2) (n = 581; 27.6 %), ineffective drug (non-
quantitative, DRP 3) (n = 387; 18.4 %), unsafe drug
(quantitative, DRP 6) (n = 181; 8.6 %), need for additional
treatment (DRP 1) (n = 146; 6.9 %) and last ineffective
drug (quantitative, DRP 4) (n = 73; 3.5 %).
Potential predictors of the occurrence of DRP were
explored but only the number of comorbidities (Spear-
man’s r = 0.412; p\ 0.001) and the number of prescribed
medicines (Spearman’s r = 0.766; p\ 0.001) were found
to be directly and significantly correlated, the latter
exhibiting a strong correlation (Fig. 4).
Most of the identified DRPs were potential (n = 2064;
97.9 %) and only 45 were manifest (2.1 %). With regard to
manifest DRPs, the majority was classified as DRP 4 (n = 27;
60 %), followed by DRP 6 (n = 9; 20 %), DRP 1 (n = 5;
11.1 %), DRP 3 (n = 3; 6.7 %) and DRP 5 (n = 1; 2.2 %).
3.2 Intervention Group
Considering only the intervention group (n = 63), a total
of 1002 DRPs were identified, of which, 697 (69.6 %)
DRPs were reported. In total, 584 (83.8 %) DRPs were
reported to the physician and 113 (16.2 %) were reported
Table 1 Baseline characteristics of 126 polypharmacy (five or more medicines) elderly (C65 years of age) Portuguese institutionalised patients
Characteristic Overall, n = 126 Intervention group, n = 63 Comparison group, n = 63 p value
Sex [n (%)] 0.563
Female 87 (69) 45 (71.4) 42 (66.7)
Male 39 (31) 18 (28.6) 21 (33.3)
Age [M (SD)] 84.8 (6.1) 85.16 (6.3) 84.5 (6) 0.525
No. of prescribed medicines [MD (SD)] 10 (4.2) 10 (4.6) 9 (3.9) 0.818
Comorbidities [MD (SD)] 4 (2.1) 4 (2) 4 (2.3) 0.670
No. of daily dosages [MD (SD)] 11 (6.2) 11 (7) 11 (5.5) 0.868
No. of total DRP (potential and manifest) [MD (SD)] 14.5 (8.4) 13 (9.2) 16 (7.5) 0.252
SD standard deviation, M mean, MD median
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to nursing staff. Reports to nurses were mainly based on
changing administration times. Pharmacist recommenda-
tions to physicians resulted from the analysis of the 584
DRPs detected and included 539 suggestions to solve or
prevent them, which could comprise dosage changes, sus-
pension or addition of medicines, and request of additional
complementary exams.
A total of 62 letters addressing 539 recommendations
were made to physicians regarding the 63 polypharmacy
elderly patients in the intervention group. Each letter
reported 9.2 DRPs on average and contained 8.7 pharma-
cist recommendations (2–19). Considering all the phar-
macist’s recommendations sent (n = 539), response was
only obtained to 172 of these (31.9 %). From responses
obtained, only 15 pharmacist recommendations were
accepted (8.7 %).
Analysing the number of recommendations made in the
letters where a positive response was obtained, it is inter-
esting to note that there is a significant association between
these two variables (Table 3).
4 Discussion
Although the sample addressed in this study was achieved
using a convenience strategy valuing geographical loca-
tion, the sample characteristics were comparable to the
reference population in the same regions, including gender
distribution. The main difference referred to the age
structure, as in the reference population, the larger age
class included those aged from 65 to 69 years and dimin-
ished progressively every 5 years, whereas the study
sample observed the opposite direction because the larger
group was represented by those aged over 85 years [1].
This fact is not surprising because the sample group used
Fig. 3 Drug classes more
frequently involved in
polypharmacy (five or more
medicines) in 126 elderly
(C65 years of age)
institutionalised Portuguese
patients
Table 2 Potential determinants
of polypharmacy in 126 elderly
(C65 years of age) Portuguese
institutionalised patients
No. of prescribed medicines p value
Sex [MD; M (SD)] 0.494
Female 10; 10.6 (3.9)
Male 9; 10.5 (4.9)
Age [Pearson’s correlation] 0.092 0.310
No. of comorbidities [Spearman’s correlation] 0.490 \0.001
SD standard deviation, M mean, MD median
Fig. 4 Correlation between the number of prescribed medicines per
patient and the presence of total drug-related problems (DRP,
manifest and potential) in 126 polypharmacy (five or more medici-
nes), elderly (C65 years of age), institutionalised Portuguese patients
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originated from nursing homes. Additionally, clinical and
therapeutic data were also comparable because the
medicines most consumed in the study sample were those
used in the most prevalent chronic conditions reported in
the National Health Enquiry [22].
Each elderly patient presented with a median of four
comorbidities registered in the medical file, around half of
the comorbidities reported elsewhere [23, 24]. Incomplete
patient records are a possible explanation for this finding,
which is consistent with the literature [25].
The initial sample was prescribed a mean of 11
medicines per day, varying between 5 and 18, which is also
similar to results published previously [11, 15, 16, 24, 27,
28].
A direct correlation between the number of comorbidi-
ties and the number of prescribed medicines (r = 0.490;
p\ 0.001) was found, as described before [29]. This is not
surprising because, as more health conditions arise, the
higher the need for additional therapy. However, no rela-
tion was found between the number of medicines and age,
contradicting previous findings [18].
The number of DRPs identified in this study was con-
siderably higher than what was expected based on previous
literature [15, 26, 27, 30, 31]. However, it should be noted
that most of these studies did not differentiate between
potential and manifest DRPs and did not use the Granada
classification, thus making comparison impossible. The
fact that very few studies were found using this classifi-
cation in nursing homes may be related to a publication
bias because this classification is originally Spanish, and
subsequently validated in Portuguese, whereas others more
frequently found arise from English-speaking countries.
Although the III Granada Consensus has been published for
some time, we opted to use the II Consensus because this is
the one adopted nationally, and the only one validated for
use in Portugal [19, 20, 32].
The more frequently found DRP was DRP 5 (35.1 %),
consistent with what has been described as ‘‘risk of adverse
drug reactions’’ [33] and as ‘‘potential interactions’’ [16].
The second more frequent DRP was DRP 2, similar to what
has been reported as ‘‘medicine with unclear indication’’
[15, 30]. However, it should be noted that there was an
enormous difference between potential and manifest DRPs,
with the latter representing only 2 % of all DRPs detected.
When analysing the types of DRPs, it becomes clear that an
important proportion is attributable to DRP 5, indicating
that most of the potential interactions detected by phar-
macists are unlikely to happen. However, it could also be
that they had not yet happened at the time, and to check it
we would need a longer follow-up. This has been reported
elsewhere [34] and thus the prioritised interventions
focussed on manifest DRP or those considered clinically
significant, which represented 70 % of the total DRPs
detected.
The possibility of information bias may not be disre-
garded as some patient files may not be totally updated or
complete, as previously described [35]. This bias, if pre-
sent, will have particular influence on DRP 2 detected,
which may not be real but rather a result of missing
information. In regard to DRP 5, it should be noted that
there was no record found for notifications made to the
pharmacovigilance system, which indicates that these were
either not made, which is in line with the low level of
reporting practiced in Portugal [36], or simply not recorded
in the patient file.
The pharmacist recommendations made to physicians
sought to address clinically relevant DRPs and included
suggestions that could solve various DRPs by therapy
changes—including the addition of new medicines, the
suspension of others and dosage change—and/or additional
monitoring, which is quite similar to what has been
reported elsewhere [16, 26, 31].
Results shown indicate there were two main drawbacks
in this study. The first was undoubtedly the high proportion
of pharmacist recommendations for which no feedback was
obtained. This could be a result of logistic problems or lack
of cooperation between different healthcare providers. Our
experience in this study strongly reinforces the latter, as
most non-response cases arose from one of the facilities
where this culture is still lacking. The second drawback of
the study was the low proportion of accepted recommen-
dations (B10 %), even if only respondents are considered.
However, two considerations are warranted. First, if we
consider the unit of analysis as the letters sent to physi-
cians, rather than the recommendations, and considering
acceptance of at least one recommendation per letter, this
value would rise to 35.7 %, suggesting this proportion of
physicians may be more open to interdisciplinary
Table 3 Association between the number of pharmacist recommendations made and physician response
Group 1: no feedback obtained to
pharmacist’s recommendation
Group 2: negative response to
pharmacist’s recommendation
Group 3: positive response to
pharmacist’s recommendation
p value
Total no. of
recommendations
367 120 52 \0.001
Mean no. of
recommendations
10.79 6.67 5.20
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collaboration, which may be seen as more encouraging for
pharmacists willing to engage in such tasks. Second, and
perhaps more important, is the fact that our data suggest
there is a reverse association between the number of
pharmacist recommendations directed at physicians and the
odds of success, i.e. the higher the number of recommen-
dations, the lower the response rate. This finding has
important implications for practice as it suggests that for
pharmacists to be successful they should be more selective
when providing recommendations. Although our data may
not be extrapolated, our experience suggests that a maxi-
mum of five recommendations should be made to increase
the odds of acceptance (p = 0.008).
Ideally, the follow-up of these patients should have been
prolonged to ensure that DRPs solved did not result in new
DRPs, which needed additional interventions. Furthermore,
more robust outcome measures would be needed to eval-
uate if DRPs solved resulted in a better health and quality
of life for the patient, which is the ultimate goal of phar-
maceutical care. However, it should be stressed that this
study is innovative by using a simple classification, with
vast use in primary care worldwide, particularly in Por-
tuguese- and Spanish-speaking countries, but with so far
little research published applying it in nursing homes res-
idents. To our knowledge, there was only one publication
describing the use of the Dader method in a similar sample,
but which did not fully characterise the prevalence or type
of DRP found [18].
5 Conclusion
Pharmacist-led medication review proved useful in identi-
fying DRPs in polypharmacy elderly patients. Closer col-
laboration between healthcare professionals is needed to
improve the acceptability of pharmacist interventions and
consequently the proportion of problems solved. Moreover,
it seems that, to be successful, the pharmacist should be
more selective in the recommendations made.
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